Oncology Central

Immunotherapy for ovarian cancer: what are the targets of the future?

0

Ovarian Cancer

Epithelial ovarian cancer affects approximately one in 70 women and is characterized by presentation at late stages resulting in poor survival outcomes, with only 45% of women surviving 5 years after diagnosis [1]. Standard treatment of ovarian cancer includes surgery and cytotoxic chemotherapy. Unfortunately, although up to 80% of women achieve clinical remission with this regimen, the majority will experience relapsed disease, the development of chemotherapy resistance, and death due to cancer-associated morbidity [2].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.